Moderna Aktie 44811242 / US60770K1079
98.65
USD
0.53
USD
0.54%
01:59:06
NDB
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Watchlist | |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Orderbuch | Analysen | |||||
| Historisch | Ausblick | |||||
Kurse + Charts + Realtime
News + Analysen
Fundamental
zugeh. Wertpapiere
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 86.81 |
| Baillie Gifford & Co. | 11.99 |
| The Vanguard Group, Inc. | 7.19 |
| Vanguard Group, Inc. (Subfiler) | 6.85 |
| State Street Corp. | 3.73 |
| Flagship Ventures Management, Inc. | 3.38 |
| Robert S. Langer, DSc | 3.02 |
| Vanguard International Growth Fund | 2.47 |
| BlackRock Fund Advisors | 2.45 |
| Scottish Mortgage Investment Trust Plc | 2.41 |
| BlackRock Institutional Trust Co. NA | 1.87 |
| Coatue Management LLC | 1.72 |
| Geode Capital Management LLC | 1.65 |
| Thélème Partners LLP | 1.64 |
| Wellington Management Co. LLP | 1.35 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 760 | 830 | 1'300 | 2'700 | 3'900 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0.18 | 0.07 | 0.62 | 6.82 | 4.90 |
Bilanz (in Mio. EUR) - Aktiva
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 1'563 | 1'129 | 6'298 | 16'071 | 13'431 |
| Summe Anlagevermögen | 1'574 | 1'311 | 2'799 | 15'061 | 20'323 |
| Summe Aktiva | 1'962 | 1'589 | 7'337 | 24'869 | 26'087 |
Bilanz (in Mio. EUR) - Passiva
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 44 | 136 | 238 | 916 | 1'200 |
| Summe Fremdkapital | 432 | 415 | 4'775 | 10'724 | 6'964 |
| Summe Eigenkapital | 1'530 | 1'175 | 2'561 | 14'145 | 19'123 |
| Summe Passiva | 1'962 | 1'589 | 7'337 | 24'869 | 26'087 |
Adresse
| 200 Technology Square, 02139 Cambridge | |
| Telefon | +1 (617) 714-6500 |
| URL | http://www.modernatx.com |
Management
|
Arpa Garay
Chief Commercial Officer |
|
Brad Miller
Chief Information Officer |
|
Charbel Haber
Senior Vice President-Regulatory Affairs |
|
Elizabeth E. Tallett
Independent Director |
|
Elizabeth G. Nabel
Independent Director |
|
Francois Nader
Independent Non-Executive Director |
|
Jacqueline Miller
Senior VP-Infectious Disease Development |
|
James M. Mock
Chief Financial Officer |
|
Jerh Collins
Chief Technical Operations & Quality Officer |
|
John Lepore
Senior Vice President-Government Engagement |
|
Jonathan Hoggatt
Director-Hematology |
|
José M. Vega
Chief Safety Officer |
|
Kate Cronin
Chief Brand Officer |
|
Lavina A. Talukdar
Senior Vice President & Head-Investor Relations |
|
Melanie Ivarsson
Chief Development Officer |
|
Noubar B. Afeyan
Chairman |
|
Patrick Norman Bergstedt
Senior Vice President-Commercial Vaccines |
|
Paul Burton
Chief Medical Officer |
|
Paul L. Sagan
Independent Non-Executive Director |
|
Paula Hammond
Scientific Advisory Board |
|
Robert S. Langer
Independent Non-Executive Director |
|
Sandra J. Horning
Independent Director |
|
Shannon Thyme Klinger
Secretary & Chief Legal Officer |
|
Stephen A. Berenson
Independent Non-Executive Director |
|
Stephen Hoge
President |
|
Stéphane Bancel
Chief Executive Officer & Director |
|
Tracey Franklin
Chief Human Resources Officer |